# Summit Therapeutics Inc. Common Stock (SMMT)

> Summit Therapeutics Inc. Common Stock (SMMT) trades at $10.67 (-9.73%) as of 7:59:30 PM EST on Nov 17, 2026, -31.47% over the past month. Market cap is $9.45B, with 9.4 days to cover in short interest.

Canonical: https://massive.com/quote/smmt
Data as of: 2026-11-18T00:59:30.189Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$10.67** -1.15 (-9.73%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$10.64** -0.03 (-0.28%)
As of 7:59:30 PM EST on Nov 17, 2026 · After hours

## Stock performance

How Summit Therapeutics Inc. Common Stock (SMMT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -9.73% |
| 1W | -40.16% |
| 1M | -31.47% |
| YTD | -38.99% |
| 1Y | -36.53% |
| 52-wk range | $10.53 – $29.23 |

From daily closes through Nov 17, 2026.

## Key statistics

Today's trading snapshot for SMMT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $10.53 – $11.91 |
| Open | $11.70 |
| Prev close | $11.82 |
| Volume | 13.17M |
| Market cap | $9.45B |
| Shares out | 799.76M |

## Valuation and profitability ratios

Valuation and profitability ratios for Summit Therapeutics Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 16.74 |
| P/FCF | — |
| ROE | -147.5% |
| ROA | -120.2% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 16, 2026

## Insider trading

[Summit Therapeutics Inc. Common Stock (SMMT) insider trading](https://massive.com/quote/smmt/insider-trading.md): open-market Form 4 buys and sells by Summit Therapeutics Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Summit Therapeutics Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Summit Therapeutics Inc. (the "Company") issued a press release announcing its financial results and operational progress for the third quarter ended September 30, 2026.”
- Sep 29, 2026 · Private placement
  “On September 28, 2026, Summit Therapeutics Inc. entered into a securities purchase agreement with AstraZeneca Holdings B.V. for the issuance and sale of 108,955.3686 shares of newly designated Class A Convertible Preferred Stock at a purchase price of $18,356.14 per share, for aggregate gross proceeds of $2.0 billion. The Preferred Shares and any shares issuable upon conversion will be issued in reliance on the exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D.”
- Sep 15, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On September 15, 2026, Summit Therapeutics Inc. issued a press release announcing that updated overall survival results from the global Phase III HARMONi clinical trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (WCLC 2026).”
- Sep 3, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On September 2, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced positive overall survival ("OS") results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression. In this preplanned analysis of OS, a secondary endpoint in HARMONi-2, Akeso reported that ivonescimab monotherapy demonstrated a statistically significant improvement compared to pembrolizumab monotherapy.”
- Aug 26, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Akeso reported that, at a pre-specified interim analysis, the ivonescimab-based regimen achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival compared to the durvalumab-based regimen. The study also met the key secondary endpoints of progression-free survival and objective response rate.”

## Similar companies

Public companies in a similar business to Summit Therapeutics Inc. Common Stock.

- [MRK](https://massive.com/quote/mrk.md) Merck & Co., Inc. (-0.76%)
- [LPA](https://massive.com/quote/lpa.md) Logistic Properties of the Americas (-1.68%)

Daily change in the latest session, 15-minute delayed.

## SMMT short interest

How heavily SMMT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 9.4 |
| Short interest | 42.26M |
| Avg volume | 4.5M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## SMMT news

The latest news and headlines about Summit Therapeutics Inc. Common Stock (SMMT).

- [Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer](https://www.zacks.com/stock/news/3031405/revolution-medicines-wins-eu-nod-for-rasonque-in-pancreatic-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3031405) · Zacks Investment Research · Nov 17, 2026 · positive sentiment
- [Summit Stock Falls on FDA Rejection for Lung Cancer Drug](https://www.zacks.com/stock/news/3030553/summit-stock-falls-on-fda-rejection-for-lung-cancer-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3030553) · Zacks Investment Research · Nov 16, 2026 · negative sentiment
- [Breakfast News: Summit’s FDA Setback Isn’t the End](https://www.fool.com/investing/breakfast-news/2026/11/16/breakfast-news/?source=iedfolrf0000001) · The Motley Fool · Nov 16, 2026 · negative sentiment
- [Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?](https://www.zacks.com/stock/news/3027269/wall-street-analysts-see-a-62-33-upside-in-summit-therapeutics-smmt-can-the-stock-really-move-this-high?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3027269) · Zacks Investment Research · Nov 10, 2026 · positive sentiment
- [SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus](https://www.zacks.com/stock/news/3023860/smmt-s-q3-earnings-beat-estimates-ivonescimab-development-in-focus?cid=CS-ZC-FT-analyst_blog|earnings_article-3023860) · Zacks Investment Research · Nov 5, 2026 · positive sentiment

## About Summit Therapeutics Inc. Common Stock

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 265 |
| Listed | Mar 5, 2015 |

[Company website](https://www.smmttx.com)

## FAQ

### What is the Summit Therapeutics Inc. Common Stock (SMMT) stock price today?

Summit Therapeutics Inc. Common Stock (SMMT) is trading at $10.67 (-9.73% on the day) as of 7:59:30 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Summit Therapeutics Inc. Common Stock?

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.

### What is the short interest in SMMT?

As of Oct 30, 2026, SMMT has 42.26M shares short and 9.4 days to cover.

### What exchange is SMMT listed on?

Summit Therapeutics Inc. Common Stock (SMMT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time SMMT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=SMMT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Summit Therapeutics Inc. Common Stock (SMMT) insider trading](https://massive.com/quote/smmt/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
